Amgen (AMGN) 67.37 0.52

Amgen, Inc.
(AMGN) 67.37 0.52

Last Trade:	67.36	Day Range:	66.80 - 67.37
Trade Time:	08:02PM	52wk Range:	47.6607 - 70.00
Prev. Close:	66.84	Market Cap:	59.04B
Open:	66.90	Div Yield:	0
Volume:	5262973	PE:	170
EPS:	4.04

The Latest On AMGN

Morgan Stanley Initiates Coverage on Amgen at Equal-weight 2/10/12 6:37am

UBS Maintains Amgen at Neutral, Lowers PT from $70 to $69 2/9/12 12:11pm

Benzinga's Top Downgrades 2/9/12 7:32am

Oppenheimer Downgrades Amgen from Outperform to Perform, Removes PT 2/9/12 7:24am

Deutsche Bank: Xgeva Not Proceeding Well for Amgen 2/8/12 10:42am

Amgen to Discuss Application for New Use of XGEVA at FDA Oncologic Drugs Advisory Committee Meeting 2/8/12 8:02am

Dendreon Rockets 17% After Critical Reveiw For Amgen's Cancer Drug 2/6/12 3:47pm

Piper Jaffray Postive on Amgen After FDA Releases Briefing Documents on Xgeva 2/6/12 11:10am

Verastem IPO Launch Captures Investors Attention 2/1/12 10:54pm

Amid Rising Repurchases, Are Buyback ETFs Worth A Look? 1/30/12 12:13pm

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12 6:24pm

Micromet Up 33% After Acquisition Announcement 1/26/12 8:53am

Morgan Stanley Initiates Coverage on Amgen at Equal-weight 2/10/12

UBS Maintains Amgen at Neutral, Lowers PT from $70 to $69 2/9/12

Benzinga's Top Downgrades 2/9/12

Oppenheimer Downgrades Amgen from Outperform to Perform, Removes PT 2/9/12

Deutsche Bank: Xgeva Not Proceeding Well for Amgen 2/8/12

Amgen to Discuss Application for New Use of XGEVA at FDA Oncologic Drugs Advisory Committee Meeting 2/8/12

Dendreon Rockets 17% After Critical Reveiw For Amgen's Cancer Drug 2/6/12

Piper Jaffray Postive on Amgen After FDA Releases Briefing Documents on Xgeva 2/6/12

Verastem IPO Launch Captures Investors Attention 2/1/12

Amid Rising Repurchases, Are Buyback ETFs Worth A Look? 1/30/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Micromet Up 33% After Acquisition Announcement 1/26/12

Verastem IPO Launch Captures Investors Attention 2/1/12

Amid Rising Repurchases, Are Buyback ETFs Worth A Look? 1/30/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Benzinga's M&A Chatter for Tuesday January 24, 2012 1/24/12

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin 12/29/11

Best Biotech Stocks of 2011 12/27/11

Jefferies Reiterates Hold, $70 PT On Watson Pharmaceuticals 12/20/11

Biotech Stocks On the Move 12/5/11

Seven Stocks Insiders Are Buying 12/2/11

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest EPS 12/2/11

Mad Money Lightning Round: Cramer Likes Waste Management 11/22/11

Morgan Stanley Initiates Coverage on Amgen at Equal-weight 2/10/12

UBS Maintains Amgen at Neutral, Lowers PT from $70 to $69 2/9/12

Benzinga's Top Downgrades 2/9/12

Oppenheimer Downgrades Amgen from Outperform to Perform, Removes PT 2/9/12

Deutsche Bank: Xgeva Not Proceeding Well for Amgen 2/8/12

Piper Jaffray Postive on Amgen After FDA Releases Briefing Documents on Xgeva 2/6/12

JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM 1/23/12

Bank of America Raises PO on Amgen to $65 12/29/11

Citigroup Maintain Buy, $73 PT on Amgen 12/27/11

UPDATE: Citi Raises Price Target on Amgen to $73 12/27/11

Citigroup Raises PT on Amgen to $73 12/27/11

Jefferies Reiterates Hold, $70 PT On Watson Pharmaceuticals 12/20/11

Trade AMGN
NOW!

Partner Headlines

Research Analyst's New Ratings ( AKS, RKT, ONXX, GILD, CELG, BIIB, BEAV, AVEO, AMGN, IDIX ) 2/10/12

10 Ex-Dividend Stocks With Buy Ratings 2/10/12

Amgen Close to 50 Day Moving Average 2/10/12

10 Ex-Dividend Stocks With Buy Ratings 2/10/12

Healthy Health Care ETF? 2/9/12

Up/Downgrades ( DMND, IM, CVS, WXS, DTV, AVID, WAG, AMGN, THOR, TRIP ) 2/9/12

4 IPOs to Watch...and None are Facebook 2/9/12

Analysts' Actions: CSCO, MMM, CIT, AMGN 2/9/12

Forget Big Pharma, It's Time For A Biotech ETF - ETF News And Commentary 2/9/12

Forget Big Pharma, It Is Time For A Biotech ETF - ETF News And Commentary 2/9/12

Zacks Bull and Bear of the Day Highlights: Amgen, Montpelier Re Holdings, Cisco Systems, Illumina and Roche Holdings - Press Releases 2/9/12

Analysts' Actions: CSCO, MMM, CIT, AMGN, S 2/9/12

Press Releases

Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting 2/8/12 Newswire Story

Faruqi & Faruqi, LLP Announces Investigation of Micromet, Inc. 1/28/12 Business Wire Story

The Law Firm of Weiss & Lurie Investigates Micromet, Inc. 1/27/12 Business Wire Story

Robbins Umeda LLP Announces an Investigation of Micromet, Inc. 1/27/12 Business Wire Story

Finkelstein Thompson LLP Announces Investigation of Micromet, Inc. 1/27/12 Business Wire Story

Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 1/27/12 Newswire Story

The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Micromet, Inc. in Connection with the Sale of the Company to Amgen Inc. 1/27/12 Business Wire Story

Amgen to Acquire Micromet 1/27/12 Newswire Story

Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results 1/24/12 Newswire Story

Critical Alerts for Amgen, Procter and Gamble, Suncor Energy, Under Armour, and Polycom Released by Seven Summits Research 1/24/12 Newswire Story

RBCC: Biotech Growing Faster than any Other Sector in Houston 1/17/12 Business Wire Story

Harris & Harris Group Notes Fifth Liquidity Event for 2011 1/10/12 GlobeNewswire Story

Get the latest AMGN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Amgen, Inc. stock price.

Amgen, Inc. by YCharts

Amgen (AMGN) 67.37 0.52

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On AMGN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social